$ACHV

Achieve Life Sciences (ACHV) draws new passive holder near 10%

Achieve Life Sciences (ACHV) reported that Logos Global Management LP and related funds filed a Schedule 13G showing passive beneficial ownership of 10,538,440 shares, or 9.99% of the class, based on 102,902,490 shares outstanding as of Aug. 11, 2026. Holdings include 6,951,032 shares, options for 1,000,000 shares, and warrants for 2,751,032 shares.

Original reporting
Published Aug 17, 2026, 11:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ACHV
Neutral
medium confidence
Mentioned
$ACHV
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ACHVNeutralLow
01

Why it matters

A near-10% passive stake disclosure can draw trading attention and raise questions about future behavior, but the filing language indicates no purpose to change or influence control.

02

Market read

Traders may monitor ACHV for follow-on filings or behavior changes, but the disclosure itself is not a fundamental catalyst.

03

What to watch

The article notes warrants and a 9.99% beneficial ownership limitation, which can constrain incremental buying and reduce the likelihood of immediate control-related moves.

Relevance 4/10Novelty 5/10Timing: after-hours filing coverage on 2026-08-17

Background

The article summarizes a Schedule 13G filing by Logos Global Management LP and affiliated funds for Achieve Life Sciences common stock.

Company-level read

Ticker impact

$ACHVNeutralMedium confidence
Context

Achieve Life Sciences disclosed via Schedule 13G that Logos Global Management and funds hold 9.99% beneficial ownership, near the 10% threshold.

Expected impact

Likely modest, short-lived volatility around the filing, with limited fundamental repricing unless follow-on actions emerge.

Evidence & confidence

The filing is a Schedule 13G (passive intent language) and the article provides ownership size and structure, not new operating or strategic actions.

Market effects

For small/mid-cap biotech, large passive stakes near 10% can increase attention from activists and other investors, but this filing alone is not a sector catalyst.

None indicated.

None indicated.

Counterpoint

Because the filing explicitly disclaims intent to influence control, the stake may be purely investment-driven and not a precursor to activism or a deal.

Key entities

  • Achieve Life Sciences, Inc.

    Subject of the Schedule 13G disclosure; beneficial ownership reported at 9.99% by Logos Global and related funds.

  • Logos Global Management LP

    Reports shared voting and dispositive power totaling 10,538,440 shares, including options and warrants.

  • Global Fund and Opportunities Fund V

    Each reported about 5% of the class as part of the aggregate 9.99% stake.

Related articles

$ACHVMed

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

ACHIEVE LIFE SCIENCES, INC. (ACHV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following

$ACHVMedAI 8/10

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Achieve Life Sciences (Nasdaq: ACHV) reported Q2 2026 results and updates on cytisinicline for nicotine dependence. The FDA issued a Complete Response Letter on June 20, 2026 citing cGMP and labeling issues, with no clinical efficacy or safety deficiencies. Achieve closed a private placement up to $354M and expects NDA resubmission in Q4 2026 and potential FDA approval in H1 2027. Cash was $187.3M at June 30, 2026.

$ACHVMed

Achieve closes $261.5M AAA HELOC securitization

Achieve announced it closed a $261.5M securitization of newly originated HELOCs, its first deal of 2026 and ninth overall. The pool covers 3,129 lines with about $261.5M unpaid principal and $276.5M total credit line as of June 30. S&P Global Ratings and Morningstar DBRS assigned ratings to six rated and three unrated note classes.

$GISMed

General Mills Announces Dana McNabb As CEO

General Mills' board elected Dana McNabb, current COO, as CEO effective January 2027, succeeding Jeff Harmening, who will become executive chair. McNabb, with 27 years at the company, has led key operating segments and functions. She aims to drive profitable growth through digital demand and supply chain modernization, building on Harmening's foundation.

$GISMed

General Mills Names First Woman CEO

General Mills has named Dana McNabb as its next CEO, the first woman to lead the company. McNabb, currently COO, will take over on January 1. Current CEO Jeff Harmening will become executive chairman. The board unanimously approved the change.